Charles Explorer logo
🇨🇿

Late-onset endothelin receptor blockade in hypertensive heterozygous REN-2 transgenic rats

Publikace na 1. lékařská fakulta, 2. lékařská fakulta, 3. lékařská fakulta |
2008

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

The aim of this study was to evaluate the role of the ET system in male heterozygous TGR with established hypertension (late-onset treatment). TGR and control Hannover Sprague'Dawley (HanSD) rats were fed a high-salt diet and were treated concomitantly with the nonselective ETA/B receptor blocker bosentan or the selective ETA receptor blocker atrasentan from day 52 of age on.

Survival rate was partly increased by bosentan and fully normalized with atrasentan. Atrasentan significantly reduced BP as early as one week after the start of the treatment.

Bosentan improved and atrasentan almost restored podocyte architecture and reversed changes in podocyte phenotype. Our results demonstrate that selective ETA receptor blockade has more favorable effects than nonselective ETA/B receptor blockade and ETA receptor blockade has similar effects in heterozygous rats with established hypertension as in young animals with developing hypertension.